Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
about
Covariate pharmacokinetic model building in oncology and its potential clinical relevance.Model-Based Individualized Treatment of Chemotherapeutics: Bayesian Population Modeling and Dose OptimizationDeterminants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapyOptimal chemotherapy for leukemia: a model-based strategy for individualized treatment.CYP2A6 genetic variation and dexmedetomidine dispositionOptimizing drug development of anti-cancer drugs in children using modelling and simulation.Pharmacogenetics in clinical pediatrics: challenges and strategies.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs.Anticoagulating obese patients in the modern era.Synthesis and anticancer activity of thiosubstituted purines.Pharmacokinetics of two 6-mercaptopurine liquid formulations in children with acute lymphoblastic leukemia.Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity.Money makes the world go round: the pervasiveness of pharmacoeconomics.Concordance between criteria for covariate model building.A First Microwave-Assisted Synthesis of a New Class of Purine and Guanine Thioglycoside Analogs.Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
P2860
Q27687599-1D563C7C-C593-4F18-9B92-892466242040Q28546915-389CDE66-C427-4D1D-AD90-FC4142CBA205Q34830088-8BBCBD2B-25AA-4374-8C04-0405CBEA18E6Q35327001-45591047-91A8-40ED-8E29-16A052E9537AQ35962388-F2858353-2AEB-48C4-87BA-52C4E6AEF3B0Q36987975-D96C86A9-7048-4CB6-8546-06C29D50B7A8Q37400384-C7AE427E-977C-44D2-BFAA-A11B301C6BAEQ37685527-CAD01A9E-367B-4853-BCD3-BED3C578C3C5Q37892531-B4440C2A-A04A-4368-BFD7-CDDCC73DD52FQ37919151-CB12FC99-291A-4541-BD49-FFC497F460C4Q38853858-EE700DC6-FDC5-4F70-9922-0640DDA91F99Q38906456-063CA777-03EC-4618-A26E-0596FFD31DF3Q41368460-444A4DEA-BB73-4C4D-BE09-F8664A1276DEQ43137171-93404B8B-E98C-4AFB-9DCA-7931551464B4Q45343385-EB3DE29C-6CD9-46B5-909D-B58532BB5F63Q50221097-FDF9E7A6-1564-4A33-89AB-2419BF5DC714Q50476254-0BB639FA-1350-4FC9-9A69-839C156BBBD9
P2860
Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Population pharmacokinetic and ...... acute lymphoblastic leukaemia.
@en
Population pharmacokinetic and ...... acute lymphoblastic leukaemia.
@nl
type
label
Population pharmacokinetic and ...... acute lymphoblastic leukaemia.
@en
Population pharmacokinetic and ...... acute lymphoblastic leukaemia.
@nl
prefLabel
Population pharmacokinetic and ...... acute lymphoblastic leukaemia.
@en
Population pharmacokinetic and ...... acute lymphoblastic leukaemia.
@nl
P2093
P2860
P1476
Population pharmacokinetic and ...... acute lymphoblastic leukaemia
@en
P2093
Anthony McCarthy
Carole Cairns
James C McElnay
Jeff S Millership
Paul S Collier
Sid Dempsey
P2860
P304
P356
10.1111/J.1365-2125.2008.03281.X
P407
P577
2008-09-23T00:00:00Z